Ravulizumab




Ravulizumab Overview

Ravulizumab (ALXN1210) (INN[1]) is a humanized monoclonal antibody designed for the treatment of paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. This drug was developed by Alexion Pharmaceuticals, Inc.[2] It was approved by the US Food and drug administration in December 2018.[3] References ^ World Health Organization (2017). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: Li...

Read more Ravulizumab Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Ravulizumab

Recent Ravulizumab Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Ravulizumab
  • Injection: 300mg/30ml(10mg/ml)
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

Other drugs which contain Ravulizumab or a similar ingredient: (1 result)






Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 23 February 2019.

We are committed to your privacy.

Copyright © 2005-2019 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 9888 W Belleview Ave #5000, Denver, CO, 80123, USA